Navigation Links
New Study Published: Lactobacillus reuteri Prodentis Effective in the Treatment of Periodontitis
Date:11/10/2010

New Study Published: Lactobacillus reuteri Prodentis Effective in the Treatment of Periodontitis -- STOCKHOLM, November 10, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries Click to view news release full screen  

New Study Published: Lactobacillus reuteri Prodentis Effective in the Treatment of Periodontitis

 
Download image

STOCKHOLM, November 10, 2010 /PRNewswire-FirstCall/ -- The study shows that L. reuteri Prodentis acts synergistically with standard treatment (scaling and root plaining, SRP) to significantly reduce probing pocket depth (PPD) and clinical attachment level (CAL) which are the two most important parameters to assess the severity of periodontitis. Furthermore L. reuteri Prodentis reveals - as the first probiotic ever - significant reductions of three different pathogens in patients with chronic periodontitis. The study also confirms the anti-inflammatory effects of L. reuteri Prodentis on gum inflammation (gingivitis).

(Photo: http://www.newscom.com/cgi-bin/prnh/20101110/418565 )

Chronic periodontitis occurs in up to 40 % of the adult population. The standard treatment aims at removing plaque in the dental pockets to reduce the periodontal pathogens and thereby prevent disease progression.

Thirty chronic periodontitis patients were included in the double blind, randomized, placebo-controlled clinical trial that lasted for 42 days. On day 0 the teeth in one half of the mouth were treated with SRP whereas the teeth in the other half were left untreated. From day 21 to day 42 the patients were supplemented with either L. reuteri Prodentis lozenges (1X108 CFU DSM 17938 and 1x108 CFU ATCC PTA 5289) or placebo lozenges twice daily.

The result showed that a combination of L. reuteri Prodentis and SRP was significantly better than all other modalities in reducing gingivitis and plaque. Moreover, L. reuteri Prodentis, either alone or following SRP, significantly reduced the pathogens Aggregibacter actinomycetemcomitans, Porphyromonas gingivalis and Prevotella intermedia by up to 90 % as compared to the treatments that did not include L. reuteri Prodentis. The combination of L. reuteri Prodentis and SRP was also significantly better than SPR alone in reducing both PPD (p<0.001) and CAL (p<0.001), see attachment.

- This short-term study proves that L. reuteri Prodentis by itself has a powerful effect on the pathogens of periodontitis and that the combination of L. reuteri Prodentis and SRP synergistically improves both PPD and CAL, says Professor Vandana at the College of Dental Science in Davangere, India. - The results strengthen L. reuteri Prodentis position as a proven treatment option for patients with periodontal disease, says Peter Rothschild, President, BioGaia AB.

The results of the study were published online on the 2nd of November 2010 in the Journal of Oral Microbiology, doi: 10.3402/jom.v2i0.5344. The study can be accessed at: http://www.journaloforalmicrobiology.net/index.php/jom/article/view/5344

BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. http://www.biogaia.com


'/>"/>
SOURCE BioGaia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD
2. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
3. Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
4. New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
5. Sermo Study Shows 63% of Physicians Would Utilize New Gout Treatments
6. Study Published This Week in Alzheimers & Dementia: The Journal of the Alzheimers Association Shows that Algal DHA Improved Memory and Learning in Healthy Adults Age 55 and Older
7. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
8. Allegheny General Hospital Study Suggests Use of Image Guided Intensity Modulated Radiation Therapy Reduces Risk of Impotency in Men Needing Radiation after Prostate Cancer Surgery
9. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
10. Hologic Announces Long-term, Five-year Results from MammoSite® ASBS Registry Study
11. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):